Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.9123.1140
Address
Level 17 350 Queen Street Melbourne, Victoria (VIC) 3000
Description
Amplia Therapeutics Ltd. is a medical biotechnology company, which engages in the development of drugs for potential use in multiple indications including oncology and chronic fibrosis. Its immuno-modulator microparticles technology can be used to induce the human immune system to fight certain cancers and infections, or modulate certain immune mechanisms implicated in autoimmune diseases such as multiple sclerosis. The company was founded by Christopher J. Burns on May 31, 2000 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.05 - 0.16
Trade Value (12mth)
AU$7,235.00
1 week
-21.67%
1 month
-30.37%
YTD
19.4%
1 year
19.4%
All time high
16.28
EPS 3 yr Growth
N/A
EBITDA Margin
N/A
Operating Cashflow
N/A
Free Cash Flow Return
N/A
ROIC
N/A
Interest Coverage
N/A
Quick Ratio
N/A
Shares on Issue (Fully Dilluted)
194m
HALO Sector
Healthcare
Next Company Report Date
02-Jun-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
26 August 24 |
Application for quotation of securities - ATX
×
Application for quotation of securities - ATX |
26 August 24 |
Change of Director's Interest Notice - Dr Chris Burns
×
Change of Director's Interest Notice - Dr Chris Burns |
23 August 24 |
Managing Director AGM Presentation
×
Managing Director AGM Presentation |
23 August 24 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
21 August 24 |
Fifth Confirmed Response in ACCENT Trial
×
Fifth Confirmed Response in ACCENT Trial |
12 August 24 |
Amplia Receives R&D Tax Rebate Totalling $3.2 Million
×
Amplia Receives R&D Tax Rebate Totalling $3.2 Million |
12 August 24 |
Change in substantial holding
×
Change in substantial holding |
09 August 24 |
Ceasing to be a substantial holder from SOL
×
Ceasing to be a substantial holder from SOL |
08 August 24 |
Ceasing to be a substantial holder from PCG
×
Ceasing to be a substantial holder from PCG |
07 August 24 |
Granting of Key Patent in Europe and Japan
×
Granting of Key Patent in Europe and Japan |
06 August 24 |
Additional Patient Response in Pancreatic Cancer Trial
×
Additional Patient Response in Pancreatic Cancer Trial |
31 July 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
25 July 24 |
Sustained Reduction in Tumour Size Seen In Pancreatic Trial
×
Sustained Reduction in Tumour Size Seen In Pancreatic Trial |
22 July 24 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
22 July 24 |
Proposed issue of securities - ATX
×
Proposed issue of securities - ATX |
19 July 24 |
Application for quotation of securities - ATX
×
Application for quotation of securities - ATX |
19 July 24 |
Section 708A Cleansing Notice
×
Section 708A Cleansing Notice |
17 July 24 |
Application for quotation of securities - ATX
×
Application for quotation of securities - ATX |
17 July 24 |
Proposed issue of securities - ATX
×
Proposed issue of securities - ATX |
12 July 24 |
Bioshares Conference Presentation
×
Bioshares Conference Presentation |
03 July 24 |
First 26 Patients recruited in Phase 2A ACCENT Trial
×
First 26 Patients recruited in Phase 2A ACCENT Trial |
02 July 24 |
Annual General Meeting to be held Friday 23 August 2024
×
Annual General Meeting to be held Friday 23 August 2024 |
25 June 24 |
Notification of cessation of securities - ATX
×
Notification of cessation of securities - ATX |
20 June 24 |
Change of Director's Interest Notice - Dr Robert Peach
×
Change of Director's Interest Notice - Dr Robert Peach |
11 June 24 |
Presentation and Webinar
×
Presentation and Webinar |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.